Scholar Rock (SRRK) Expected to Announce Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is projected to issue its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of ($0.86) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $47.01 on Tuesday. The stock’s 50-day moving average is $45.20 and its 200 day moving average is $38.52. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of -14.92 and a beta of 0.67. Scholar Rock has a 1-year low of $22.71 and a 1-year high of $49.82. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41.

Insider Activity at Scholar Rock

In other news, General Counsel Junlin Ho sold 9,580 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $445,757.40. Following the sale, the general counsel owned 241,545 shares in the company, valued at approximately $11,239,088.85. The trade was a 3.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mo Qatanani sold 7,989 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $46.53, for a total transaction of $371,728.17. Following the completion of the sale, the insider directly owned 106,929 shares in the company, valued at $4,975,406.37. This represents a 6.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 336,448 shares of company stock valued at $14,971,883. 13.30% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds have recently bought and sold shares of SRRK. Caitong International Asset Management Co. Ltd bought a new position in shares of Scholar Rock during the fourth quarter valued at approximately $30,000. Summit Securities Group LLC purchased a new stake in shares of Scholar Rock in the 4th quarter worth approximately $31,000. Strs Ohio purchased a new stake in shares of Scholar Rock in the 1st quarter worth approximately $77,000. US Bancorp DE increased its position in Scholar Rock by 81.6% during the 3rd quarter. US Bancorp DE now owns 2,822 shares of the company’s stock valued at $105,000 after buying an additional 1,268 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in Scholar Rock during the fourth quarter valued at $114,000. Institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on SRRK shares. JPMorgan Chase & Co. increased their target price on shares of Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Wolfe Research assumed coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price target on the stock. Barclays boosted their price objective on Scholar Rock from $45.00 to $52.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. UBS Group assumed coverage on Scholar Rock in a research note on Wednesday, January 7th. They set a “buy” rating and a $60.00 price objective for the company. Finally, Citigroup started coverage on shares of Scholar Rock in a research note on Friday, January 9th. They issued a “buy” rating and a $55.00 target price on the stock. Four analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $51.14.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).